Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy. Revach OY, Cicerchia AM, Shorer O, et al. Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy. bioRxiv : the preprint server for biology. 2024. doi:10.1101/2024.02.12.579184 Read more